Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.
* Better-than-expected Q3 earnings, all segments up q-o-q * We raise our EBIT estimates by 4-3% for ...
Redeye comments on Isofol’s announcement that the European Patent Office (EPO) has issued an “Intent...
* Q3 a bump in the road * Estimates down given more cautious view on activity pick-up * 2025e-'27e E...
Fastighetsbolaget Trianon levererade ett starkt tredje kvartal med 33 procent högre förvaltningsresu...
Omsättningen kom in linje med Analysguidens estimat och uppgick till 7,9 (9,7) meur, varav PremierGa...
Thunderful reported sales and EBITDA that exceeded our expectations.
* Q3 sales SEK 46m (vs. ABGSCe 60m), EBIT -3m (vs. ABGSCe -2m) * Better than expected cost control *...
Redeye provides its initial take on Navigo’s Q3 2025 report, which missed our sales projection sligh...
Redeye comments on Nekkar’s Q3 report that missed our expectations, mainly driven by a continued low...
Redeye provides its initial take on Surgical Science’s Q3 2025 report, which came in slightly below ...
IDL’s Q3 report missed our forecast on sales, owing to fluctuations in APAC for TUBEX.
Redeye comments on the KOL event 12 November. The KOL's opinions strenghten our conviction in a succ...
* Signs new phase-1 contract for Norrbotten power line * Phase-2, starting 2026, could be the larges...
Starbreeze continues to demonstrate a strong foundation through the enduring success of Payday 2, wh...
Redeye provides a research update following the Q3 report published by Isofol earlier today.
Redeye notes that InfraCom's Q3 2025 net sales met expectations, but EBITDA was impacted by operatin...
Redeye notes that BeammWave’s Q3 2025 report was in line with its EBITDA forecast, due to OPEX being...
Redeye comments on Alligator presenting new data on mitazalimab at SITC 40th Anniversary Annual Meet...
I dag offentliggjorde Angler Gaming (”Angler” eller ”Bolaget”) sin delårsrapport för kv3 2025.
